Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026 (IMAGE)

Dana-Farber Cancer Institute

Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026

Caption

Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, presented the results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on Oct. 24.

Credit

ESMO

Usage Restrictions

Please credit ESMO for use of photo

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.